Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
A new weight loss drug could beat Ozempic's side effect problem
The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose pounds with fewer side effects than current anti-obesity medications on the market.
Novo Nordisk Earnings Are Here. Wegovy Sales Beat Estimates for Weight Loss Drug.
Novo Nordisk posted solid quarterly results Wednesday before the market open.Sales came in at 71.3 billion Danish crowns ($10.3 billion) and diluted earnings per share of DKK 6.12 in the third quarter.
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs.
Novo Nordisk’s Wegovy sales jump on international rollouts
Novo’s obesity drug sales nearly doubled outside the U.S. during the quarter as global demand continued to rise.
Novo Nordisk maintains booming sales of obesity and diabetes drugs
Novo Nordisk maintained its sales growth momentum on booming sales of its weight loss and diabetes drugs, as it reported revenue and operating profit broadly in line with analysts’ expectations. The maker of the blockbuster Ozempic and Wegovy drugs has benefited in recent years from huge demand for its products.
Novo Nordisk says its experimental drug CagriSema has similar side effects to Wegovy
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
Novo Nordisk’s Wegovy Sales Surge on Crucial US Market
Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt in the third quarter, a potential relief for investors after rival Eli Lilly & Co. reported disappointing obesity sales last week.
Novo Nordisk’s Blockbuster Wegovy Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
Novo Nordisk's quarterly Wegovy sales beat forecast, shares rise
Novo Nordisk reported on Wednesday better-than-expected quarterly sales of its popular Wegovy weight-loss drug, reassuring investors worried the drugmaker was losing its lead in the fast-growing obesity drug market to U.
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
An injection pen of Zepbound, Eli Lilly’s weight-loss drug, is displayed in New York City, December 11, 2023.
WebMD12h
New FDA Warning Added to Popular Weight Loss Drugs
Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...
Can new weight loss drugs fight the US obesity epidemic? Here's what to know
Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer new weight loss drugs?
Microdosing Ozempic? Why some people are playing doctor with weight-loss drugs
the Hollywood resident found herself mixing vials in her kitchen to create her own doses of a popular weight-loss drug.
Ozempic, Wegovy or Mounjaro: the battle of the weight-loss injections
Ozempic, Wegovy or Mounjaro: the battle of the weight-loss injections - As weight-loss injections emerge as key players in ...
WebMD6d
Weight Loss Drugs May Be a New Alternative to Knee Replacements
A new study suggests that weekly self-injections of the weight loss drug semaglutide could reduce knee pain from moderate osteoarthritis by nearly 50%.
The Jerusalem Post Blogs on MSN3d
Weight loss injections ease knee pain - study
The drug semaglutide, sold under the brand name Ozempic for diabetes management and Wegovy for weight loss, has now ...
News Medical on MSN2d
Weight loss drug semaglutide may offer relief for knee arthritis pain
Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.
Viking Therapeutics' New Weight Loss Pill Shows Promising Results
Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...